Enanta Pharm (ENTA) Posts Mixed Q3 Results

Enanta Pharm (NASDAQ: ENTA) reported Q3 EPS of $2.61, $0.94 better than the analyst estimate of $1.67. Revenue for the quarter came in at $42.1 million versus the consensus estimate of $40.83 million.

For earnings history and earnings-related data on Enanta Pharm (ENTA) click here.

You May Also Be Interested In

• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Independent Bank receives regulatory approval for HCB Financial acquisition
• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$221 at BMO Capital